The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Authors :: W.J. Sisso
Igor Odintsov
Lukas Delasos
Marissa Mattar
Eric Gladstone
E.M. Sisso
Shawn M. Leland
M. Ladanyi
Morana Vojnic
D. Plessinger
Inna Khodos
Romel Somwar
E. De Stanchina
Allan Jo-Weng Lui
Source :: European Journal of Cancer. 138:S15-S16
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Cancer Research
Oncology
Chemistry
medicine.drug_class
Cell culture
medicine
Seribantumab
Monoclonal antibody
Molecular biology

Full Text Access

Tools